Omalizumab prevents anaphylactoid reactions to mRNA COVID‐19 vaccine-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Omalizumab prevents anaphylactoid reactions to mRNA COVID‐19 vaccine

Published:2021-08-10 Issue:11 Volume:35 Page:
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Smola A.¹,Samadzadeh S.²,Müller L.³,Adams O.³,Homey B.¹,Albrecht P.²,Meller S.¹^ORCID

Affiliation:

1. Department of Dermatology Medical Faculty Heinrich‐Heine‐University Duesseldorf Germany

2. Department of Neurology Medical Faculty Heinrich‐Heine‐University Duesseldorf Germany

3. Institute of Virology Medical Faculty Heinrich‐Heine‐University Duesseldorf Germany

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.17549

Reference4 articles.

1. COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee

2. Acute Allergic Reactions to mRNA COVID-19 Vaccines

3. Omalizumab and hypersensitivity reactions

4. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status;Dermatology and Therapy;2023-09-30

2. Characteristics of immune response profile in patients with immediate allergic and autoimmune urticarial reactions induced by SARS-CoV-2 vaccines;Journal of Autoimmunity;2023-07

3. Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273) COVID-19 mRNA vaccines and hypersensitivity reactions;Journal of the National Medical Association;2022-12

4. Impact of Omalizumab on Anaphylaxis in Patients Treated for Chronic Urticaria;International Archives of Allergy and Immunology;2022-11-03

5. Urticaria relapse after mRNA COVID ‐19 vaccines in patients affected by chronic spontaneous urticaria and treated with antihistamines plus omalizumab: A single‐center experience;Dermatologic Therapy;2022-09-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3